GMP News and Research

RSS

Leading CROs and CDMOs turn to mass photometry for rapid protein, mRNA and viral vector analytics

Refeyn, developer of pioneering mass photometry technology, expands its global adoption across contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs).

3 Mar 2026

JPM highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO platform delivering sustainable high growth

JPM Highlights | WuXi Biologics CEO Dr. Chris Chen: Scaled CRDMO Platform Delivering Sustainable High Growth

From WuXi Biologics 27 Jan 2026

WuXi Biologics and Hanchorbio enter strategic partnership to advance next-generation bi- and multi-functional fusion protein pipeline

WuXi Biologics, a global leading Contract Research, Development and Manufacturing Organization (CRDMO), and HanchorBio Inc., a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, jointly announced today the signing of a strategic collaboration agreement on the development and manufacturing of multiple next-generation bi-/multi-functional fusion programs from HanchorBio's pipeline.

27 Jan 2026

New partnership aims to expand global access to sickle cell gene therapy

Caring Cross, a 501(c)(3) non-profit dedicated to improving access to advanced therapies, and Boston Children's Hospital today announced a collaboration to provide a sustainable, affordable pathway for patients to access stem cell gene therapies for the treatment of Sickle Cell Disease (SCD).

22 Jan 2026

Novel immunotherapy targeting pancreatic cancer shows promising results in phase 1/2 trial

A recent publication in Nature Medicine describes a novel immunotherapy targeting pancreatic cancer that has shown promising results in a first in-human phase 1/2 trial.

13 Jan 2026

Remodeling the tumor microenvironment to unlock CAR-T cell potential

Chimeric antigen receptor T (CAR-T) cell therapy has revolutionized hematologic cancer treatment, but its efficacy in solid tumors remains limited by poor infiltration into the complex tumor microenvironment (TME).

22 Dec 2025

CHITOSE and FUJIFILM Biosciences form strategic alliance to drive global innovation and biopharmaceutical manufacturing

Chitose Laboratory Corp., (CHITOSE), a leading company of the bioeconomy and provider of advanced cell line development services, and FUJIFILM Biosciences Inc., a global leader in the innovation and manufacture of cell culture solutions for the life science market, today announced a new strategic alliance that leverages the strengths of both companies in advancing biopharmaceutical production.

18 Dec 2025

UC Irvine receives funding for clinical trial of neural stem cell therapy for Huntington's disease

Leslie M. Thompson, Donald Bren Professor of psychiatry and human behavior as well as neurobiology and behavior at the University of California, Irvine, has received an $11,999,933 grant from the California Institute for Regenerative Medicine for an unprecedented clinical trial of a novel neural stem cell therapy for Huntington's disease.

12 Dec 2025

Rentschler Biopharma and Coriolis Pharma announce strategic collaboration for integrated biopharma solutions

Rentschler Biopharma, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, and Coriolis Pharma, a globally operating contract research and development organization (CRDO) and a leader in formulation research and development for biopharmaceuticals, today announced a strategic collaboration.

From Rentschler Biopharma SE 2 Dec 2025

Promising long-term vaccine for Crimean-Congo hemorrhagic fever developed

Crimean-Congo hemorrhagic fever (CCHF) is one of the world's most dangerous yet overlooked infectious diseases.

22 Nov 2025

Celleo Biotech uses INTEGRA's PIPETBOY GENIUS to improve reproducibility and efficiency

Celleo Biotech is using the PIPETBOY GENIUS serological pipet controller from INTEGRA Biosciences to streamline the development and manufacturing of novel cell and gene therapies.

From INTEGRA Biosciences 13 Nov 2025

Researchers achieve long-term remission with novel T cell therapies for HPV-related cancers

Researchers from Rutgers Cancer Institute, New Jersey's only National Cancer Institute (NCI) - designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes of Health, announced findings from two HPV-related studies that highlight the potential of novel T cell therapies to achieve long-lasting remission and complete tumor regression in patients with advanced epithelial cancers.

10 Nov 2025

BIOVECTRA and Revolution Biomanufacturing partner to deliver integrated mRNA Design and GMP production services

BIOVECTRA, a part of Agilent Technologies Inc., and Revolution Biomanufacturing Inc. today announced a collaboration that grants BIOVECTRA access to Revolution Biomanufacturing's proprietary platforms for optimizing untranslated regions (UTRs) and codon usage to enhance mRNA stability and translational efficiency.

6 Nov 2025

Hijacking cellular machinery within cancer cells to promote antitumor immunity

Investigators from Mass General Brigham have developed a way to promote antitumor immunity by hijacking cellular machinery within cancer cells.

3 Nov 2025

How IoT, AI, and mobile technologies are transforming manufacturing and R&D

Explore how the convergence of IoT, AI, and mobile technologies is driving digital innovation in manufacturing and R&D.

From LabVantage Solutions 16 Oct 2025

Reimagining light scattering for biotherapeutics

Wyatt Technology's DynaPro Plate Reader 4 integrates advanced light scattering techniques, optimizing workflows in biotherapeutic and nanoparticle research.

From Waters | Wyatt Technology 13 Oct 2025

PlasmidFactory and Fraunhofer IZI join forces to advance non-viral cell and gene therapies

PlasmidFactory GmbH and the Fraunhofer Institute for Cell Therapy and Immunology IZI have signed a Memorandum of Understanding to combine expertise in cell therapy process development and GMP manufacturing, aiming to accelerate non-viral cell and gene therapies for the benefit of patients.

From PlasmidFactory GmbH 9 Oct 2025